Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022

Rhea-AI Summary

Prothena Corporation plc (NASDAQ:PRTA) will announce its fourth quarter and full year 2021 financial results on February 17, 2022, after U.S. market close. The announcement will be followed by a live audio conference call at 4:30 PM ET, accessible via the company's website. Prothena is a biotech firm focused on therapeutics for neurodegenerative and rare diseases, leveraging expertise in protein dysregulation. Their pipeline includes candidates for AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's diseases.

Positive

• Strong pipeline targeting neurodegenerative diseases and rare amyloid conditions.
• Potential for significant impact in treating conditions with few current options.

Negative

• None.

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.

The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.

To access the call via dial-in, please dial (888) 440-6385 (U.S. and Canada toll free) or +1 00 646-960-0180 (international) five minutes prior to the start time and refer to conference ID number 92750. A replay of the call will be available until March 3, 2022 via dial-in at (800) 770-2030 (U.S. toll free) or +00 1 647 362-9199 (international), Conference ID Number 92750.

About Prothena

Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts:

Media
Eric Endicott, Senior Vice President, Corporate Affairs
650-448-3670, eric.endicott@prothena.com

Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com

FAQ

When will Prothena report its Q4 2021 financial results?

Prothena will report its Q4 2021 financial results on February 17, 2022, after the U.S. market close.

What is the focus of Prothena's pipeline?

Prothena's pipeline focuses on investigational therapeutics for neurodegenerative diseases and rare peripheral amyloid diseases.

How can I access the Prothena conference call?

The conference call can be accessed by dialing (888) 440-6385 for U.S. participants or +1 646-960-0180 for international callers.

What diseases is Prothena developing treatments for?

Prothena is developing treatments for AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases.